[Ovid] Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction每associated steatohepatitis (MASH) and fibrosis

Ph_teko Post time 1 hour(s) ago | Show all posts |Read mode
This post will be closed automatically in 2026-11-07 19:42
Reward10points

journalㄩHepatology

AuthorsㄩZobair M. Younossi; Maria Stepanova; Andrei Racila; Linda Henry; Dominic Labriola; Rebecca Taub; Fatema Nader

Published dateㄩ2025-4-

DOIㄩ10.1097/hep.0000000000001084

PDF linkㄩhttps://journals.lww.com/10.1097/HEP.0000000000001084

Article linkㄩhttps://doi.org/10.1097/hep.0000000000001084

Article SourceㄩOvid Technologies (Wolters Kluwer Health)﹝


Remarkㄩ
Reply

Use magic Donate Report

All Reply0 Show all posts

Reply

You have to log in before you can reply Login | Register

Points Rules

Intermediate member
  • post

  • reply

  • points

    380


Return to the list